Analysis of p53, p21Waf1/Cip1 and TGF-β3 immunohistochemical staining in Bowen's disease

被引:9
作者
Kawakami, T
Soma, Y
Mizoguchi, M
Saito, R
机构
[1] St Marianna Univ, Sch Med, Dept Dermatol, Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
[2] Toho Univ, Sch Med, Dept Dermatol 2, Tokyo, Japan
关键词
p53; p21(Waf1/Cip1); transforming growth factor beta(3); Bowen's disease;
D O I
10.1159/000051577
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The p53 gene is one of a family of tumor suppressor genes that have been implicated in the genesis of a wide variety of malignant neoplasms including Bowen's disease. Its role in oncogenesis and tumor progression is thought to be of importance. Transforming growth factor beta (TGF-beta) is the most potent known inhibitor of the progression of normal epithelial cells through the cell cycle, p21(Waf1/Cip1) is thought to mediate p53 signaling induced by DNA-damaging agents to arrest the cell cycle. Objective: The present study evaluates the expression of p53, p21(Waf1/Cip1) and TGF-beta (3) protein and speculates on their role in Bowen's disease. Methods: Sixteen patients seen at our clinic between 1993 and 2000 were examined. We analyzed p21(Waf1/Cip1), p53 and TGF-beta (3) immunohistochemical staining in all specimens. Results: In 7 of the Bowen's disease patients, overexpression of p53-positive cells was present in the middle and basal layers, and intense staining of p21(Waf1/Cip1) was observed in the upper spinous layers. In the other 9 Bowen's disease patients, we found positively stained cells for p21(Waf1/Cip1) but negative p53 immunostaining in the upper epidermal layer. Downregulated TGF-beta (3) expression was detected in all layers except the upper spinous layers. Conclusion: These observations suggest different roles for p21(Waf1/Cip1) and p53 within abnormal cells in Bowen's disease. p21(Waf1/Cip1) may induce terminal differentiation to the superficial layer in Bowen's disease via either a p53-independent or -dependent pathway. Moreover, downregualtion of TGF-beta (3) immunostaining provides relevant information concerning the pathogenesis of Bowen's disease. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:9 / 15
页数:7
相关论文
共 31 条
  • [1] Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells
    Akagi, M
    Yasui, W
    Akama, Y
    Yokozaki, H
    Tahara, H
    Haruma, K
    Kajiyama, G
    Tahara, E
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1996, 87 (04): : 377 - 384
  • [2] Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development
    Amendt, C
    Schirmacher, P
    Weber, H
    Blessing, M
    [J]. ONCOGENE, 1998, 17 (01) : 25 - 34
  • [3] Immunohistochemical nuclear staining for p53, PCNA, and Ki-67 in different histologic variants of basal cell carcinoma
    Barrett, TL
    Smith, KJ
    Hodge, JJ
    Butler, R
    Hall, FW
    Skelton, HG
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (03) : 430 - 437
  • [4] TP53 TUMOR-SUPPRESSOR GENE AND SKIN CARCINOGENESIS
    BASSETSEGUIN, N
    MOLES, JP
    MILS, V
    DEREURE, O
    GUILHOU, JJ
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 103 (05) : S102 - S106
  • [5] Casey G, 1996, ONCOGENE, V13, P1971
  • [6] CUI W, 1994, CANCER RES, V54, P5831
  • [7] FUNCTIONAL-ANALYSIS OF THE TRANSFORMING GROWTH-FACTOR-BETA RESPONSIVE ELEMENTS IN THE WAF1/CIP1/P21 PROMOTER
    DATTO, MB
    YU, Y
    WANG, XF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (48) : 28623 - 28628
  • [8] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [9] ELDEIRY WS, 1995, CANCER RES, V55, P2910
  • [10] p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest
    Ewen, ME
    [J]. JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 128 (04): : 355 - 360